Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > ViRexx Announces Failure to Secure an Alternative Equivalent Funder to Replace LM Funds Corp.

Abstract:
ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living announces that it has been unable to secure alternative equivalent financing to replace the funding LM Funds Corp. ("LM") failed to advance as the Standby Guarantor for the Company's rights offering.

ViRexx Announces Failure to Secure an Alternative Equivalent Funder to Replace LM Funds Corp.

Edmonton, AB, Canada | Posted on September 15th, 2008

As a result of LM's failure to meet its standby commitment related to the Company's rights offering and the lack of alternative equivalent financing, the following actions have taken place:

- The following members of the Board have tendered their resignation effective September 14, 2008: Jacques LaPointe, Douglas Gilpin, Yves Cohen and Michael Marcus;

- Darrell Elliott will remain as Chairman of the Board of Directors and interim Chief Executive Officer;

- All other officers of the Company, including the Chief Financial Officer, Brent Johnston, CA, have resigned effective September 14, 2008; and

- All of the employees of the Company have been laid off indefinitely.

Management intends to appoint an operating committee to manage the day-to-day operations of the Company and oversee an orderly restructuring of its assets.

Shareholders who deposited funds for the purchase of common shares under the rights offering will receive a full refund of their subscription funds from the Company through Computershare Investor Services Inc., the Subscription Agent under the rights offering.

####

About ViRexx Medical Corp.
ViRexx is a Canadian-based development-stage biotech company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living. Our platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and nanoparticle applications, select solid tumors and late-stage ovarian cancer.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX has not approved or disapproved of the information contained herein.

For more information, please click here

Contacts:
ViRexx Medical Corp.
Darrell Elliott
Chairman and Chief Executive Officer
(780) 433-4411
(780) 436-0068 (FAX)
Email:

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Flexible electronics integrated with paper-thin structure for use in space January 17th, 2025

‘Brand new physics’ for next generation spintronics: Physicists discover a unique quantum behavior that offers a new way to manipulate electron-spin and magnetization to push forward cutting-edge spintronic technologies, like computing that mimics the human brain January 17th, 2025

Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025

How a milk component could eliminate one of the biggest challenges in treating cancer and other disease, including rare diseases: Nebraska startup to use nanoparticles found in milk to target therapeutics to specific cells January 17th, 2025

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Nanomedicine

How a milk component could eliminate one of the biggest challenges in treating cancer and other disease, including rare diseases: Nebraska startup to use nanoparticles found in milk to target therapeutics to specific cells January 17th, 2025

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Announcements

Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025

How a milk component could eliminate one of the biggest challenges in treating cancer and other disease, including rare diseases: Nebraska startup to use nanoparticles found in milk to target therapeutics to specific cells January 17th, 2025

The National Space Society Congratulates SpaceX on Starship’s 7th Test Flight: Latest Test of the Megarocket Hoped to Demonstrate a Number of New Technologies and Systems January 17th, 2025

The National Space Society Congratulates Blue Origin on the Inaugural Flight of New Glenn: The Heavy Lift Reusable Rocket Will Open New Frontiers and Provide Healthy Competition January 17th, 2025

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project